Zaolai Pharmaceutical: Net profit attributable to the parent company in the first quarter increased by 10.18% year-on-year.

Sali Pharmaceutical announced on April 26th that the company achieved a first quarter revenue of 898 million yuan in 2026, an increase of 8.90% compared to the same period last year. The net profit attributable to the shareholders of the listed company was 200 million yuan, compared to 181 million yuan in the same period last year, an increase of 10.18%. The basic earnings per share was 0.2846 yuan.